170 related articles for article (PubMed ID: 36924180)
21. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.
Capdevila J; Bodei L; Davies P; Gorbounova V; Jensen RT; Knigge UP; Krejs GJ; Krenning E; O'Connor JM; Peeters M; Rindi G; Salazar R; Vullierme MP; Pavel ME; ;
Neuroendocrinology; 2019; 108(1):18-25. PubMed ID: 30153686
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
Wee CE; Costello BA; Orme JJ; Quevedo JF; Pagliaro LC
Prostate; 2021 Sep; 81(13):938-943. PubMed ID: 34254332
[TBL] [Abstract][Full Text] [Related]
23. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Gupta A; Duque M; Saif MW
JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience.
Bardasi C; Spallanzani A; Benatti S; Spada F; Laffi A; Antonuzzo L; Lavacchi D; Marconcini R; Ferrari M; Rimini M; Caputo F; Santini C; Cerma K; Casadei-Gardini A; Andrikou K; Salati M; Bertolini F; Fontana A; Dominici M; Luppi G; Gelsomino F
Endocrine; 2021 Dec; 74(3):707-713. PubMed ID: 34231124
[TBL] [Abstract][Full Text] [Related]
25. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
[TBL] [Abstract][Full Text] [Related]
26. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
Kim ST; Ha SY; Lee J; Hong SN; Chang DK; Kim YH; Park YA; Huh JW; Cho YB; Yun SH; Lee WY; Kim HC; Park YS
Medicine (Baltimore); 2016 May; 95(19):e3534. PubMed ID: 27175651
[TBL] [Abstract][Full Text] [Related]
27. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms.
Zhang Y; Shang L; Zhang PP; Chen LH; Wang W; Fang C; Qiu M; Feng XY; Zhou L; Zhang M; Tan HY; Qiu XD; Wang H; Lin R; Zhang Q; Zeng YJ; Jin KZ; Yu XJ; Shen L; Chen MH; Li J; Li LP; Chen J
Cancer Med; 2019 Sep; 8(11):5000-5011. PubMed ID: 31293053
[TBL] [Abstract][Full Text] [Related]
29. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
30. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
31. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
32. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
34. [Neuroendocrine tumors: analysis of 252 cases].
Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
[TBL] [Abstract][Full Text] [Related]
35. Modified staging system for gastric neuroendocrine carcinoma based on American Joint Committee on Cancer and European Neuroendocrine Tumor Society systems.
Lu J; Zhao YJ; Zhou Y; He Q; Tian Y; Hao H; Qiu X; Jiang L; Zhao G; Huang CM;
Br J Surg; 2020 Feb; 107(3):248-257. PubMed ID: 31971627
[TBL] [Abstract][Full Text] [Related]
36. [Pathology of neuroendocrine neoplasms].
Anlauf M; Gerlach P; Schott M; Raffel A; Krausch M; Knoefel WT; Pavel M; Klöppel G
Chirurg; 2011 Jul; 82(7):567-73. PubMed ID: 21487814
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
39. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
Lamarca A; Frizziero M; Barriuso J; McNamara MG; Hubner RA; Valle JW
Clin Transl Oncol; 2019 Jul; 21(7):950-953. PubMed ID: 30506132
[TBL] [Abstract][Full Text] [Related]
40. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
